pacira pharmaceuticals inc (PCRX) Key Developments
Pacira Pharmaceuticals, Inc. - Analyst/Investor Day
Jan 8 15
To provide an overview of the company's future expansion plans for additional EXPAREL indications, as well as the leading DepoFoam-based product candidates
Pacira Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full-Year of 2014
Jan 8 15
Pacira Pharmaceuticals, Inc. provided revenue guidance for the fourth quarter and full-year of 2014. For the fourth quarter, the company expects total revenues of $61.8 million in the fourth quarter of 2014, which represents an increase of 84% over $33.6 million in the fourth quarter of 2013.
For the full year 2014, the company expects total revenues of $197.7 million in 2014, a 13% increase over $85.6 million in 2013.
Pacira Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 08:30 AM
Nov 25 14
Pacira Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 08:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Dave Stack, president, chief executive officer and chairman.
Pacira Pharmaceuticals, Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014
Nov 21 14
Pacira Pharmaceuticals, Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014 . Venue: Convene (Formerly Sentry Centers), 730 3rd Avenue, New York, New York, United States.
Pomerantz LLP Files a Class Action Lawsuit Against Pacira Pharmaceuticals, Inc. and Certain of its Officers
Nov 17 14
Pomerantz LLP has filed a class action lawsuit against Pacira Pharmaceuticals, Inc. and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-06172, is on behalf of a class consisting of all persons or entities who purchased Pacira securities between April 9, 2012 and September 24, 2014, inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the class period, Defendants made false and/or misleading statements, and failed to disclose material adverse facts about the company's business, operations, prospects and performance. Specifically, during the class period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the company was overstating the efficacy of its Exparel drug; (ii) the company was improperly promoting its Exparel drug by touting its ability to be effective for up to 72 hours, when in fact, it is only approved for 24 hours of pain relief; (iii) the company improperly claimed that Exparel is safe for use in cholecystectomy and colectomy procedures, when in fact, approved labeling does not provide instructions for, or indicate that Exparel will be safe and effective for postsurgical pain, if used in surgical procedures other than hemorrhoidectomy or bunionectomy; (iv) a substantial portion of the company's revenues were derived from off label marketing; and (v) and as a result of the above, the Company's financial statements were materially false and misleading at all relevant times.